Hunterian Medicine

Main focus: Gene editing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-MAD7, other undisclosed

Funding stage: Private

Location: Cambridge, MA, USA

Website: https://www.hunterian.com/

Partners: Inscripta

Hunterian Medicine aims to enable CRISPR delivery within the limited AAV packaging capacity that currently represents one of the major challenges within therapeutic genome editing. The company is exploring a range of diseases and orphan indications for licensing and/or development, although it has yet to disclose targets and indications for its lead therapeutic programme.

Hunterian Medicine

Your Latest CMN News

Tackling Antibiotic-Resistant Staphylococcus...

CMN Interview

Nov. 18, 2024

Researchers in Japan have used phagemids for the delivery of CRISPR components to bacteriophage, selectively killing multi-drug resistant bacteria in...

CMN Weekly (15 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 15, 2024

Some of the best links we picked up around the internet

CRISPR Screens Identify Vital lncRNAs

CMN Briefs

Nov. 12, 2024

American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than...

CMN Weekly (8 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 8, 2024

Some of the best links we picked up around the internet

Researchers Report Fewer Large DNA Deletions After...

CMN Briefs

Nov. 7, 2024

Researchers in Korea report that large DNA deletions occur during DNA repair at a much lower frequency for base editors and prime editors than for...

FDA Clears First CRISPR-Cas13 RNA-Editing Trial...

CMN Clinical

Nov. 6, 2024

The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...